AI-generated analysis. Always verify with the original filing.
OnKure Therapeutics, Inc. reported Q4 and full year 2025 financial results, including $59.1 million in cash and cash equivalents as of December 31, 2025, R&D expenses of $10.7 million, G&A expenses of $3.4 million, and net loss of $13.5 million or $0.99 per share. The company highlighted progress in the PIKture-01 trial of OKI-219 and expects to announce updated data and a next-generation PI3Kα pan-mutant inhibitor in March 2026.
Event Type
Disclosure
Mandatory
Variant
8-K
and Item 9.01 (including Exhibit 99.1) of this report shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as am
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release titled "OnKure Therapeutics Reports Fourth Quarter and Full Year 202
| Metric | Value | Basis |
|---|---|---|
| Research and development | $10.7K | GAAP |
| General and administrative | $3.4K | GAAP |
| Net loss | $13.5K | GAAP |
| Net loss per share | $-0.99 | GAAP |